{"nctId":"NCT02431806","briefTitle":"Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder","startDateStruct":{"date":"2015-06-23","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":552,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Levomilnacipran 40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran"]},{"label":"Levomilnacipran 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran"]},{"label":"Fluoxetine 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fluoxetine"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Levomilnacipran","otherNames":["Fetzima"]},{"name":"Fluoxetine","otherNames":["Prozac"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female outpatients;12-17 years of age\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for MDD, confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children--Present and Lifetime (K-SADS-PL)\n* Score ≥ 40 on the Children's Depression Rating Scale-Revised (CDRS-R) at Visits 1 and 2\n* Clinical Global Impressions-Severity (CGI-S) score ≥ 4 at Visits 1 and 2\n* Reliable caregiver\n* Physical examination, vital signs, clinical laboratory tests, and electrocardiogram (ECG) normal or not clinically significant\n\nKey Psychiatric Exclusion Criteria:\n\n* DSM-IV-TR-based diagnosis of an axis I disorder other than MDD that is the primary focus of treatment\n* Mental retardation or amnestic or other cognitive disorders\n* Significant suicide risk:\n* Suicide attempt within the past year OR\n* Investigator judgment (based on psychiatric interview and Columbia-Suicide Severity Rating Scale (C-SSRS))\n\nKey Treatment-Related Exclusion Criteria:\n\n* Allergy, intolerance, or hypersensitivity to levomilnacipran, milnacipran, fluoxetine, or any other selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)\n* Use of prohibited concomitant medication that cannot be discontinued\n\nOther Key Medical Exclusion Criteria:\n\n* Any current medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or affect participants safety\n* Liver enzyme tests aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \\> 2X the upper limit of normal (ULN)\n* Clinically significant cardiovascular disorders\n* Seizure disorder or risk of seizure\n* Drug or alcohol abuse or dependence (within the past year)\n* Positive urine drug screen or blood alcohol","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score","description":"CDRS-R is a 17-item scale measuring presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.90","spread":"1.09"},{"groupId":"OG001","value":"-23.28","spread":"1.11"},{"groupId":"OG002","value":"-22.64","spread":"1.12"},{"groupId":"OG003","value":"-24.37","spread":"1.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale","description":"The CGI-S is a clinician-rated scale used to rate the severity of the participants current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1= Very much improved; 2= Much improved; 3= Minimally improved; 4= No change; 5= Minimally worse; 6= Much worse; 7= Very much worse. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.54","spread":"0.10"},{"groupId":"OG001","value":"-1.52","spread":"0.10"},{"groupId":"OG002","value":"-1.52","spread":"0.10"},{"groupId":"OG003","value":"-1.68","spread":"0.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":141},"commonTop":["Headache","Nausea","Tachycardia","Vomiting","Decreased appetite"]}}}